Topic

Antiviral Therapy

Fillmore has investigated the critical role of antiviral therapies in preventing the progression of COVID-19 to severe disease, particularly among high-risk and immunocompromised populations. His research demonstrates that oral antiviral treatments significantly reduce the likelihood of severe outcomes in patients using immune-suppressive drugs. Additionally, his work highlights a substantial gap in care, noting that provider failure to offer these medications often leads to the underuse of essential preventive therapies.

U.S. Veterans and VA Data 2 COVID-19 2 Severe COVID-19 2 Solid Organ Transplantation 2 Electronic Health Records 1 Vaccine Effectiveness 1 Risk Factors 1 Logistic Regression 1 Immunosuppressive Therapy 1 Rheumatoid Arthritis 1 Observational Study 1 Retrospective Cohort Study 1

Publications (2)

2024

Risk of severe coronavirus disease 2019 despite vaccination in patients requiring treatment with immune-suppressive drugs: A nationwide cohort study of US Veterans.

Sonia T. Anand, Austin D. Vo, Jennifer La, Mary Brophy, Nhan V. Do, Nathanael R. Fillmore, Westyn Branch-Elliman, Paul A. Monach

Transplant Infectious Disease26(1), e14168

U.S. Veterans and VA Data Electronic Health Records COVID-19 Severe COVID-19 Vaccine Effectiveness

2024

Underuse of Antiviral Drugs to Prevent Progression to Severe COVID-19 - Veterans Health Administration, March-September 2022.

Paul A. Monach, Sonia T. Anand, Nathanael R. Fillmore, Jennifer La, Westyn Branch-Elliman

MMWR: Morbidity and Mortality Weekly Report73(3), 57-61

U.S. Veterans and VA Data COVID-19 Severe COVID-19 Antiviral Therapy Hematologic Malignancies